Results 151 to 160 of about 2,681,651 (342)

Mutation N856K in spike reduces fusogenicity and infectivity of Omicron BA.1

open access: yesSignal Transduction and Targeted Therapy, 2023
Chunyun Sun   +9 more
doaj   +1 more source

Advancements in the application of reporter gene cell lines in bioactivity evaluation of biological products

open access: yesBioresources and Bioprocessing
The assessment of biological product activity is a key aspect of quality control. Currently, in vitro assays serve as the primarily method employed by both companies and regulatory agencies to evaluate biological activity.
Kaijuan Yi, Can Wang, Huili Lu
doaj   +1 more source

Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro [PDF]

open access: yesIranian Journal of Immunology, 2017
Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy.
Reza Hosseini-Ghatar   +7 more
doaj  

Variable major proteins of Borrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides. [PDF]

open access: yes, 1985
The variable major proteins (VMP) of serotypes 7 and 21 of the relapsing fever agent Borrelia hermsii were isolated by detergent extraction and high performance liquid chromatography.
Barbour, AG   +3 more
core  

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini   +13 more
wiley   +1 more source

Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial

open access: yesContemporary Clinical Trials Communications
Background/Objective: The neutralizing monoclonal antibody against SARS-CoV-2 is regarded as one of the most effective therapies for COVID-19.: This study was a randomized, double-blinded, placebo-controlled Phase II trial conducted to evaluate the ...
Jorge Diaz   +4 more
doaj   +1 more source

Neutralization of budded Autographa californica NPV by a monoclonal antibody: identification of the target antigen. [PDF]

open access: yes, 1984
A neutralizing monoclonal antibody of the budded phenotype of Autographa californica nuclear polyhedrons virus did not react with the occluded form of the virus as determined by neutralization, ELISA, and indirect immunoperoxidase staining.
Faulkner, P   +3 more
core  

Analysis of T cell activation requirements with the use of alloantigens or an anti-clonotypic monoclonal antibody. [PDF]

open access: bronze, 1986
Christine Hua   +4 more
openalex   +1 more source

Decreased Serum 5‐HT: Clinical Correlates and Regulatory Role in NMJ of MG

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Although 5‐Hydroxytryptamine (5‐HT) indirectly stimulates muscle contraction and participates in regulating Acetylcholine receptor (AChR) cluster homeostasis in cellular, animal, and clinical studies, evidence regarding its potential to modulate muscle contraction in myasthenia gravis (MG) remains limited.
Xinru Shen   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy